Patent applications published 13 October 2010

Published: 15-Nov-2010

Selected patent applications from the weekly European Patents Bulletin


  • Novel formulation
    Glaxo Group 2237662*

  • (Het) aryl-p-quinone derivatives for treatment of mitochondrial diseases
    Edison Pharmaceuticals 2237664*

  • HCV protease inhibitors and uses thereof
    Avila Therapeutics 2237666*

  • HCV protease inhibitors and uses thereof
    Avila Therapeutics 2237667*

  • Phenylephrine pharmaceutical formulations and compsns for transmucosal absorption
    Schering-Plough Healthcare Products 2237767*

  • Formulations of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridine-2-yl)benzoic acid
    Vertex Pharmaceuticals Inc 2237768*

  • Biocompatible protein particles, particle devices and methods thereof
    Gel-Del Technologies 2237770*

  • Pharmaceutical compsns comprising granules of purified microbial lipase and methods of preventing or treating digestive disorders
    Abbott Products 2237771*

  • Method and multilayered device for controlled topical delivery of therapeutic agents to the skin
    Newmedical Technologies 2237772*

  • Compsns and methods for improving cardiovascular health
    HealthSpan Solutions 2237776*

  • Compsns and methods for treating neurodegenerative diseases
    Marine Bio 2237777*

  • Methods of treating hematologic cancers using PNP inhibitors such as forodesine in combination with alkylating agents or anti-CD20 agents
    Biocryst Pharmaceuticals 2237778*

  • Benzothiazole and benzoxazole derivatives and methods of use
    Abbott Laboratories 2237779*

  • Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives
    Meda 2237780*

  • Pharmaceutical compsn comprising tesofensine or its analogue and an anti-obesity agent
    NeuroSearch 2237781*

  • Use of tetrahydropyrimidines
    Bitop 2237782*

  • Method of optimising the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib
    Novartis 2237783*

  • Activators of executioner procaspases 2, 6 and 7
    The Regents of the University of California 2237784*

  • Triarylmethane analogues and their use in treating cancers
    Emory University 2237785*

  • Use of inhibitors of connexin43 for treatment of fibrotic conditions
    Coda Therapeutics 2237786*

  • Decoy influenza therapies
    Massachusetts Institute of Technology 2237787*

  • Aerosolised nitrite and nitric oxide-donating compounds and uses thereof
    Aires Pharmaceuticals 2237788*

  • Treatment of intervertebral disc degeneration using human umbilical cord tissue-derived cells
    Ethicon 2237789*

  • Attenuated oncolytic paramyxoviruses encoding avian cytokines
    Bayer Schering Pharma 2237790*

  • Means for smoking cessation
    Ds-pharma 2237791*

  • Anti-C35 antibody combination therapies and methods
    Vaccinex 2237792*

  • Inhibitors of cathepsin B
    Virobay 2237793*

  • Chimeric HIV fusion proteins as vaccines
    Healthbanks USA; Healthbanks Biotech; Liao, Chao-Wei; Chang, Hsiu-Kang 2237794*

  • Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
    Coda Therapeutics 2237795*

  • Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions
    Coda Therapeutics 2237796*

  • Antibody targeting through a modular recognition domain
    The Scripps Research Institute 2237797*

  • Prodrug comprising a self-cleavable linker
    Ascendis Pharma 2237799*

  • Biodegradable contrast agents
    Iopharma Technologies 2237800*

  • MR imaging agent or medium comprising hyperpolarised 13C alanine and methods of imaging wherein such an imaging medium is used
    GE Healthcare 2237801*

  • Method to produce hyperpolarised amino acids and aminosulphonic agents
    GE Healthcare 2237802*

  • Treatment and prophylaxis of amyloidosis
    Elan Pharmaceuticals 2237803*

  • Method for sterilisation of chemically activated solid support materials
    GE Healthcare Bio-Sciences 2237804*

  • Imiqimod formulation
    Dow Pharmaceutical 2237805*

  • Pulverised fibrin clots and pharmaceutical compsns containing them
    Metamorefix 2237806*

  • Hydrogel compsns and uses thereof
    Zimmer 2237807*

  • Open-pore biocompatible surface coating for an implant, method for producing the same, and use thereof
    Smith & Nephew Orthopaedics 2237808*

  • Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor agonist; and pharmaceutical compsns containing the same
    Amorepacific Corp 2238105*

  • Process for the manufacture of a 6-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene derivative
    Boehringer Ingelheim International 2238107*

  • Salt forms of a 6-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene derivative, process for their manufacture and pharmaceutical compsns containing same
    Boehringer Ingelheim International 2238108*

  • 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist against biological activity
    Allergan 2238109*

  • 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as antagonists for urotensine II receptors
    Sanofi-Aventis 2238111*

  • 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of secretase (BACE)
    Janssen Pharmaceutica 2238112*

  • N-[3-bromo-2-chloro-4-(4,5-dihydro-1H-imidazol-2-ylmethyl)-phenyl]-methanesulphoamide as alpha-1A adrenergic partial agonist for the treatment of incontinence
    F Hoffmann-La Roche 2238113*

  • Novel imdazolinylmethyl aryl sulphonamides
    F Hoffmann-La Roche 2238114*

  • Novel imdazolinylmethyl aryl sulphonamides
    F Hoffmann-La Roche 2238115*

  • Novel imdazolinylmethyl aryl sulphonamides
    F Hoffmann-La Roche 2238116*

  • 4-phenyl-piperazin-1-yl-alkyl-benzoimidazol-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
    NeuroSearch 2238117*

  • Method of synthesis of bosentan, its polymorphic forms and its salts
    Cipla 2238118*

  • Quinazolines and related heterocyclic compounds, and their therapeutic use
    Vereniging voor Christelijk Hoger Onderwijs 2238119*

  • Improved process for making triphenylboron-pyridine compound
    Invista Technologies 2238120*

  • UVA filter based on ascorbic acid derivatives
    Merck Patent 2238121*

  • Preparation of sulfamide derivatives
    Janssen Pharmaceutica 2238122*

  • Addition reaction to fluoroallylfluorosulphate
    Solvay Solexis 2238123*

  • A process for the production of cyclic diesters of alpha-hydroxyacids
    Ktanton 2238124*

  • Novel aryl piperazine derivatives useful as modulators of dopamine and serotonin receptors
    NeuroSearch 2238125*

  • Derivatives of tetrahydroquinoxaline urea, preparation thereof and therapeutic application thereof
    Sanofi-Aventis 2238126*

  • Pyrazole-carboxamide derivatives as P2Y12 antagonists
    Sanofi-Aventis 2238127*

You may also like